Home/Filings/4/0001209191-22-061178
4//SEC Filing

Curley Joanne 4

Accession 0001209191-22-061178

CIK 0001831828other

Filed

Dec 13, 7:00 PM ET

Accepted

Dec 14, 4:08 PM ET

Size

20.3 KB

Accession

0001209191-22-061178

Insider Transaction Report

Form 4
Period: 2022-12-12
Curley Joanne
Chief Development Officer
Transactions
  • Exercise/Conversion

    Class A Common Stock

    2022-12-12$11.00/sh+6,900$75,90033,721 total
  • Sale

    Class A Common Stock

    2022-12-13$18.28/sh11,733$214,44126,821 total
  • Sale

    Class A Common Stock

    2022-12-13$18.19/sh1,078$19,60926,821 total
  • Sale

    Class A Common Stock

    2022-12-12$18.25/sh6,900$125,92426,821 total
  • Exercise/Conversion

    Class A Common Stock

    2022-12-13$6.37/sh+1,078$6,87027,899 total
  • Exercise/Conversion

    Class A Common Stock

    2022-12-13$11.00/sh+11,733$129,06338,554 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2022-12-1311,73365,384 total
    Exercise: $11.00Exp: 2031-05-12Class A Common Stock (11,733 underlying)
  • Exercise/Conversion

    Stock Options (right to buy)

    2022-12-126,90077,117 total
    Exercise: $11.00Exp: 2031-05-12Class A Common Stock (6,900 underlying)
  • Exercise/Conversion

    Stock Options (right to buy)

    2022-12-131,0788,639 total
    Exercise: $6.37Exp: 2030-03-31Class A Common Stock (1,078 underlying)
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022.
  • [F2]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.41, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F3]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.09 to $18.92, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F4]1/4 of the shares subject to the option vested on May 13, 2022, and 1/48 of the shares vest monthly thereafter.
  • [F5]1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter.

Issuer

Vera Therapeutics, Inc.

CIK 0001831828

Entity typeother

Related Parties

1
  • filerCIK 0001857670

Filing Metadata

Form type
4
Filed
Dec 13, 7:00 PM ET
Accepted
Dec 14, 4:08 PM ET
Size
20.3 KB